View Our Videos & Question More

Proventus.org.uk

Charity No 1131517 Ltd Company by guarantee No 5386441

 

Copyright©proventus.org.uk 2012  Terms & Conditions  Disclaimer

Fryers Place

Forum

Equipping People To Make Sense Of What They Are Told

Report Abuse of The Blue Badge Scheme
Read Our Blog & Question More

Orally administered immunomodulatory compound developed as a disease modifying treatment.

A new type of immumodulatory agent for relapsing remitting multiple sclerosis (RRMS), led to a 40% reduction in lesions, according to results of a multicentre, placebo-controlled phase IIb trial.

Laquinimod affects the levels of certain cytokines (substances released by immune cells) and reduces the passage of immune cells into the brain and spinal cord.

Laquinimod is a novel once-daily, orally administered immunomodulatory compound developed as a disease modifying treatment for multiple sclerosis (MS).

A recent Phase II study of oral laquinimod concluded that it is well tolerated and effective in suppressing development of active MRI lesions in relapsing MS. Treatment over six months resulted in a 30% decrease in MRI disease activity. those with disease activity at the start of the study showed a decrease of more than 40%.

A second, 9-month phase II study, using a higher dose has been recently completed, showing a statistically significant effect on decreasing the number of active lesions in the brain, as well as a clear trend of reducing the number of clinical relapses.

Phase III clinical trials are in preparation

 

 

Source: Teva Pharmaceutical Industries Ltd

Polman C et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64(6):987-991.

The Lancet - Comi G, et al "Effect of laquinimod on MRI-monitored disease activity in aptients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study" Lancet 2008; 371: 2085-2092. (20/06/08)

 

 

 

Report Side Effects - Site Page

 

 

 

 

 

 

 

 

 

 

Laquinimod